Idexx Laboratories [IDXX] vs Iqvia Holdings [IQV] Detailed Stock Comparison
Idexx Laboratories
NASDAQ
Loading...
Iqvia Holdings
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Idexx Laboratories wins in 10 metrics, Iqvia Holdings wins in 9 metrics, with 0 ties. Idexx Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Idexx Laboratories | Iqvia Holdings | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 51.08 | 26.05 | Iqvia Holdings |
| Price-to-Book Ratio | 34.07 | 5.59 | Iqvia Holdings |
| Debt-to-Equity Ratio | 84.81 | 272.12 | Idexx Laboratories |
| PEG Ratio | 1.05 | -1.18 | Iqvia Holdings |
| EV/EBITDA | 37.47 | 15.69 | Iqvia Holdings |
| Profit Margin (TTM) | 24.41% | 7.88% | Idexx Laboratories |
| Operating Margin (TTM) | 33.62% | 13.39% | Idexx Laboratories |
| EBITDA Margin (TTM) | 33.62% | 13.39% | Idexx Laboratories |
| Return on Equity | 64.87% | 19.79% | Idexx Laboratories |
| Return on Assets (TTM) | 23.26% | 5.16% | Idexx Laboratories |
| Free Cash Flow (TTM) | $798.08M | $2.11B | Iqvia Holdings |
| 1-Year Return | 32.69% | -11.09% | Idexx Laboratories |
| Price-to-Sales Ratio (TTM) | 12.29 | 2.06 | Iqvia Holdings |
| Enterprise Value | $52.19B | $45.85B | Idexx Laboratories |
| EV/Revenue Ratio | 12.93 | 2.92 | Iqvia Holdings |
| Gross Profit Margin (TTM) | 62.62% | 32.94% | Idexx Laboratories |
| Revenue per Share (TTM) | $50 | $89 | Iqvia Holdings |
| Earnings per Share (Diluted) | $12.14 | $7.29 | Idexx Laboratories |
| Beta (Stock Volatility) | 1.56 | 1.32 | Iqvia Holdings |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Idexx Laboratories vs Iqvia Holdings Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Idexx Laboratories | 2.21% | 2.53% | -0.88% | 16.79% | 48.70% | 55.03% |
| Iqvia Holdings | 0.27% | 15.65% | 11.21% | 24.11% | 17.19% | 4.73% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Idexx Laboratories | 32.69% | 90.21% | 58.20% | 755.96% | 1,949.27% | 3,904.04% |
| Iqvia Holdings | -11.09% | 13.31% | 22.54% | 192.62% | 382.05% | 382.05% |
News Based Sentiment: Idexx Laboratories vs Iqvia Holdings
Idexx Laboratories
News based Sentiment: MIXED
IDEXX demonstrated continued strong financial performance and raised its long-term outlook, but insider selling and mixed institutional activity introduced some caution. The company's overall trajectory remains positive, but these factors warrant investor attention and monitoring as we approach the Q3 earnings report on October 30, 2025.
Iqvia Holdings
News based Sentiment: POSITIVE
September saw a surge in positive analyst activity, significant institutional investment, and the launch of a potentially game-changing AI-powered solution. While a Zacks downgrade provides a counterpoint, the overall narrative is strongly positive, indicating continued growth and strengthening market position for IQVIA.
Performance & Financial Health Analysis: Idexx Laboratories vs Iqvia Holdings
| Metric | IDXX | IQV |
|---|---|---|
| Market Information | ||
| Market Cap | $49.74B | $35.54B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 409,804 | 1,153,140 |
| 90 Day Avg. Volume | 397,098 | 1,175,690 |
| Last Close | $633.84 | $204.34 |
| 52 Week Range | $356.14 - $688.12 | $134.65 - $237.34 |
| % from 52W High | -7.89% | -13.90% |
| All-Time High | $706.95 (Jul 26, 2021) | $285.61 (Dec 27, 2021) |
| % from All-Time High | -10.34% | -28.45% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.11% | 0.05% |
| Quarterly Earnings Growth | 0.45% | -0.27% |
| Financial Health | ||
| Profit Margin (TTM) | 0.24% | 0.08% |
| Operating Margin (TTM) | 0.34% | 0.13% |
| Return on Equity (TTM) | 0.65% | 0.20% |
| Debt to Equity (MRQ) | 84.81 | 272.12 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $18.20 | $33.99 |
| Cash per Share (MRQ) | $2.06 | $12.87 |
| Operating Cash Flow (TTM) | $905.81M | $2.62B |
| Levered Free Cash Flow (TTM) | $625.74M | $2.45B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Idexx Laboratories vs Iqvia Holdings
| Metric | IDXX | IQV |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 51.08 | 26.05 |
| Forward P/E | 51.85 | 15.74 |
| PEG Ratio | 1.05 | -1.18 |
| Price to Sales (TTM) | 12.29 | 2.06 |
| Price to Book (MRQ) | 34.07 | 5.59 |
| Market Capitalization | ||
| Market Capitalization | $49.74B | $35.54B |
| Enterprise Value | $52.19B | $45.85B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 12.93 | 2.92 |
| Enterprise to EBITDA | 37.47 | 15.69 |
| Risk & Other Metrics | ||
| Beta | 1.56 | 1.32 |
| Book Value per Share (MRQ) | $18.20 | $33.99 |
Financial Statements Comparison: Idexx Laboratories vs Iqvia Holdings
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | IDXX | IQV |
|---|---|---|
| Revenue/Sales | $998.43M | $4.02B |
| Cost of Goods Sold | $375.05M | $2.69B |
| Gross Profit | $623.38M | $1.32B |
| Research & Development | $59.06M | N/A |
| Operating Income (EBIT) | $316.53M | $538.00M |
| EBITDA | $351.81M | $813.00M |
| Pre-Tax Income | $310.08M | $323.00M |
| Income Tax | $67.41M | $56.00M |
| Net Income (Profit) | $242.68M | $266.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | IDXX | IQV |
|---|---|---|
| Cash & Equivalents | $163.97M | $2.04B |
| Total Current Assets | $1.32B | $6.35B |
| Total Current Liabilities | $1.14B | $7.57B |
| Long-Term Debt | $546.80M | $14.39B |
| Total Shareholders Equity | $1.45B | $5.79B |
| Retained Earnings | $5.58B | $6.58B |
| Property, Plant & Equipment | $833.62M | $816.00M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | IDXX | IQV |
|---|---|---|
| Operating Cash Flow | $235.07M | $459.00M |
| Capital Expenditures | $-30.03M | $-151.00M |
| Free Cash Flow | $207.94M | $292.00M |
| Debt Repayment | N/A | $-1.74B |
| Common Stock Repurchase | $-400.89M | $-657.00M |
Short Interest & Institutional Ownership Analysis
| Metric | IDXX | IQV |
|---|---|---|
| Shares Short | 2.12M | 4.68M |
| Short Ratio | 5.41 | 3.92 |
| Short % of Float | 0.03% | 0.03% |
| Average Daily Volume (10 Day) | 409,804 | 1,153,140 |
| Average Daily Volume (90 Day) | 397,098 | 1,175,690 |
| Shares Outstanding | 81.60M | 176.10M |
| Float Shares | 79.12M | 161.46M |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 0.97% | 1.02% |
Dividend Analysis & Yield Comparison: Idexx Laboratories vs Iqvia Holdings
| Metric | IDXX | IQV |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |